FDA 483 - Aditya Bardia, M.D. - August 17, 2018

An FDA inspection of Aditya Bardia, M.D. in Boston, MA, identified a significant deviation in the conduct of a clinical trial. The firm failed to follow its investigational plan by not reporting specific subject conditions and responses as mandated by the study protocol. This indicates a serious lapse in adherence to clinical trial procedures.